Iovance Biotherapeutics Inc (IOVA) (Q3 2026) Earnings Call Highlights: Record $122 Million ...
Iovance Biotherapeutics Inc (IOVA) posts 80% year-over-year revenue growth, expands its cash runway into 2029, and advances lung cancer and sarcoma programs toward 2027-2029 regulatory submissions. Related Stocks: IOVA ,